Core Viewpoint - The company announced that its wholly-owned subsidiary, the Innovative Drug Research Center, has received approval from the National Medical Products Administration for clinical trials of HW241045 tablets, which are intended for the treatment of idiopathic pulmonary fibrosis. This drug is classified as a Class 1 chemical drug, and currently, there are no approved drugs targeting the same mechanism globally [1]. Company Summary - The company is actively advancing its drug development pipeline with the approval of HW241045 for clinical trials [1]. - HW241045 is positioned as a novel treatment option for idiopathic pulmonary fibrosis, a condition with significant unmet medical needs [1]. - The approval marks a significant milestone as it indicates the company's commitment to innovation in the pharmaceutical sector [1].